Arrowhead Pharmaceuticals 10Q 2024 Q1 Quarterly report | ARWR Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: advisory, apply, applying, ASU, August, bearing, BofA, CFB, clearance, convenience, Cowen, credit, deducting, discrete, DMPK, Dyslipidemia, Dystrophia, dystrophy, East, endeavor, ESOP, Facioscapulohumeral, HBV, Hoyt, Hypertriglyceridemia, IV, kinase, mediated, meet, muscular, myotonic, myotonica, notified, plant, Plozasiran, quantitative, reconciliation, reconciling, remeasured, renal, SHEET, Statement, statute, strive, subsidiary, threshold, type, uncertain, underwriting, Zodasiran

Removed: accumulation, acquired, active, adverse, affiliated, announced, arm, assessment, balanced, began, burden, categorized, classified, collected, commencement, community, conducted, conform, consistent, construct, continuing, Corporation, create, DE, depend, directly, district, earned, emergent, England, entirety, equivalent, estimation, evenly, exit, expanding, expended, expensed, fall, fixed, generated, globule, guaranteed, Halozyme, histologic, ICAV, identical, impacted, implementation, increment, incremental, indirectly, infrastructure, invest, JJDC, Johnson, joint, Journal, line, local, low, lowest, median, met, minimum, NDA, observability, observable, observed, optimization, orderly, partial, performed, Pharmaceutical, placebo, premium, presentation, proportional, published, quoted, ratably, reach, readily, readout, receiving, refundable, regression, reimbursable, reimbursed, represented, reversal, significance, similar, simultaneously, software, Sorrento, SPA, spent, stake, state, sublease, successful, top, Unadjusted, undisclosed, unobservable, Valley, venture, Vivo, WEDC

Arrowhead Pharmaceuticals (ARWR) 10-Q2024 Q1 Quarterly report

Content analysis